Company Insights

TEM customer relationships

Explore interactive graphBrowse insights index
TEM customer relationship map

Tempus AI (TEM): Customer Relationships that Shape Cashflow and Risk

Tempus operates at the intersection of clinical genomics, AI-enabled insights, and clinical trial services, monetizing through a mix of data licensing, multi-year access subscriptions, fee-for-service lab testing, and bespoke clinical research work. Its go-to-market concentrates on pharmaceutical and biotechnology sponsors, health systems, and government payers, while strategic collaborations and financing arrangements underpin capital and product expansion.

For a concise view of how these customer and partner relationships affect valuation and operational risk, visit https://nullexposure.com/ for structured exposure reporting.

Why the customer map matters to investors

Tempus’s revenue model blends high-margin licensing and subscription revenue with variable-fee clinical services and diagnostics, creating a hybrid cashflow profile: recurring revenue from access agreements plus lumpy, usage-based receipts tied to testing volumes and trial work. Key company-level signals drawn from reported constraints and filings:

  • Contracting posture: A mix of short-term payment cycles (typical billing 30–120 days) and product delivery structures that include one-time rights to use, time-based access licenses, and fee-for-service engagements. This creates partial predictability (subscriptions and signed TCV) alongside volume sensitivity (clinical testing, fee-for-service).
  • Concentration and criticality: Tempus serves very large pharmaceutical companies and government payers; the firm reports significant concentration with a small number of customers accounting for a material share of Data and Services revenue, which creates customer dependence risk.
  • Revenue maturity: Contracts span one-time licensed deliveries to multi-year access arrangements and service agreements; AI applications are early-stage within revenue mix while core lab services and data/access products are mature revenue drivers.
  • Operational constraints: Heavy U.S. operations, non-redundant lab facilities, and exposure to Medicare/Medicaid reimbursement practices create policy and operational execution risk.

Customer and partner relationships, name by name

Below are the relationships surfaced in Tempus’s public disclosures and press coverage, each summarized with the source reference.

Ares Capital Corporation

Tempus reports a senior secured term loan facility with Ares that contributed to its total indebtedness, establishing Ares as a lender providing structured credit rather than a traditional customer relationship. According to Tempus’s FY2024 Form 10‑K (period ended December 31, 2024), $272.4 million of its indebtedness was outstanding under the Term Loan Facility with Ares Capital Corporation.

Google LLC

Google is the counterparty to a convertible promissory note that Tempus classifies within its total indebtedness; this financing relationship reflects strategic capital alignment rather than a pure commercial customer contract. Tempus’s FY2024 Form 10‑K shows $168.2 million outstanding under a convertible promissory note issued to Google as part of the company’s reported $440.6 million in indebtedness.

AstraZeneca AB

Tempus issued a warrant to AstraZeneca in conjunction with a Master Services Agreement signed in November 2021, indicating a commercial collaboration that included equity-linked economics. The FY2024 Form 10‑K notes the warrant issuance tied to the November 2021 MSA with AstraZeneca.

Pathos

Tempus has executed a range of commercial agreements with Pathos covering access to the company’s Lens product, sequencing services, clinical research organization capabilities, and other data services — a supplier-customer collaboration across product and services lines. That arrangement is described in Tempus’s FY2024 Form 10‑K as covering Lens access, sequencing, CRO and other services.

Whitehawk Therapeutics (WHWK)

Tempus entered a collaboration to provide access to its de‑identified multimodal database to inform Whitehawk’s biomarker-driven oncology trial design and patient selection, a commercially typical pharma partnership to support clinical development. This collaboration was announced in a March 10, 2026 press release reported by The Globe and Mail and covered by Parameter.io, stating Whitehawk will apply Tempus’ de‑identified multimodal database to target patient populations for clinical trials.

Mid‑analysis: what these relationships collectively signal

Collectively, the relationships show a company financed partly by strategic capital (Google note) and traditional leveraged credit (Ares), while commercial exposure is tilted to large pharma collaborations and clinical services customers. The FY2024 disclosures also show meaningful remaining contracted value: Tempus reported signed contracts with Remaining Total Contract Value (TCV) exceeding $940 million, including about $300 million of potential opt‑ins — a strong visibility anchor for future revenue.

For more granular investor intelligence on counterparty exposures and contract profiles, explore https://nullexposure.com/ for tailored reports.

Investment implications and risk checklist

Investors should weigh these dynamics as follows:

  • Revenue visibility vs. concentration: The signed TCV and multi-year access deals provide visibility, but revenue concentration is material — Tempus stated $111.6 million (approximately 46% of its Data and Services product line revenue) came from three customers in 2024, creating client‑specific downside risk.
  • Payment and reimbursement sensitivity: With Medicare representing a substantial share of clinical testing volume (26% of clinical testing volume in 2024), policy and payer reimbursement changes materially affect cash receipts and margins.
  • Contract mix drives margin variability: Licensing and subscription contracts support recurring, higher-margin revenue recognized over time, while fee‑for‑service and usage-based contracts introduce volume-driven variability and shorter billing cycles.
  • Capital structure and strategic partners: The convertible note to Google and the Ares term loan increase leverage but also signal strategic and institutional investor backing; these instruments influence liquidity and refinancing sensitivity.
  • Operational concentration: Labs concentrated in several U.S. locations create service concentration risk if capacity or regulatory issues arise.

Key takeaways:

  • High upside for recurring access contracts and signed TCV, balanced by meaningful customer concentration and reimbursement exposure.
  • Financing relationships with Google and Ares provide capital but also impose debt service and potential dilution vectors.

What to watch next

Monitor developments in: (1) renewal or expansion of top customer contracts (any movement changes concentration risk), (2) Medicare/Medicaid reimbursement policy updates that affect diagnostic volumes, and (3) any amendments to the Google convertible note or Ares credit facility that alter capital structure.

For ongoing tracking of counterparty exposure, contract TCV, and material client concentration, visit https://nullexposure.com/ to subscribe to expanded reports and alerts.

Tempus’s commercial footprint — a blend of large pharma collaborations, government payer exposure, and strategic financing partners — defines both its growth runway and its principal investors’ risk vectors. Investors should balance the company’s meaningful contractual visibility and strategic relationships against concentration, reimbursement sensitivity, and leverage when modeling forward cashflow and valuation.